Cargando…
Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment
BACKGROUND: Assessing neuropsychiatric symptoms (NPS) in older adults is important for determining dementia risk. Mild behavioral impairment (MBI) is an at-risk state for cognitive decline and dementia, characterized by emergent NPS in later life. MBI has significantly higher dementia incidence than...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504997/ https://www.ncbi.nlm.nih.gov/pubmed/32597801 http://dx.doi.org/10.3233/JAD-200011 |
_version_ | 1783584732963930112 |
---|---|
author | Naude, James P. Gill, Sascha Hu, Sophie McGirr, Alexander Forkert, Nils D. Monchi, Oury Stys, Peter K. Smith, Eric E. Ismail, Zahinoor |
author_facet | Naude, James P. Gill, Sascha Hu, Sophie McGirr, Alexander Forkert, Nils D. Monchi, Oury Stys, Peter K. Smith, Eric E. Ismail, Zahinoor |
author_sort | Naude, James P. |
collection | PubMed |
description | BACKGROUND: Assessing neuropsychiatric symptoms (NPS) in older adults is important for determining dementia risk. Mild behavioral impairment (MBI) is an at-risk state for cognitive decline and dementia, characterized by emergent NPS in later life. MBI has significantly higher dementia incidence than late life psychiatric conditions. However, its utility as a proxy for neurodegeneration has not been demonstrated. Plasma neurofilament light (NfL) is a validated biomarker of axonal damage, and has been shown to associate with hallmarks of neurodegeneration. OBJECTIVE: The purpose of this investigation was to identify associations between NfL rate of change and the presence of MBI symptomatology. METHODS: We evaluated the association of MBI with changes in NfL in a cohort (n = 584; MBI + n = 190, MBI– n = 394) of non-demented participants from the Alzheimer’s Disease Neuroimaging Initiative. MBI was determined by transforming Neuropsychiatric Inventory Questionnaire items using a published algorithm. Change in NfL was calculated over 2 years. RESULTS: Time*MBI status was the only significant interaction to predict change in NfL concentrations (F(1,574) = 4.59, p = 0.032), even after controlling for age, mild cognitive impairment, and demographics. Analyses reclassifying 64 participants with new onset MBI over 2 years similarly demonstrated greater increases in NfL (F(1,574) = 5.82, p = 0.016). CONCLUSION: These findings suggest MBI is a clinical proxy of early phase neurodegeneration with putative utility in identifying those at dementia risk. MBI can be used as a case ascertainment approach to capture those at high risk for cognitive decline and dementia, and is an important construct for clinicians dealing with cognitive and neuropsychiatric symptomatology in older adults. |
format | Online Article Text |
id | pubmed-7504997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75049972020-10-06 Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment Naude, James P. Gill, Sascha Hu, Sophie McGirr, Alexander Forkert, Nils D. Monchi, Oury Stys, Peter K. Smith, Eric E. Ismail, Zahinoor J Alzheimers Dis Research Article BACKGROUND: Assessing neuropsychiatric symptoms (NPS) in older adults is important for determining dementia risk. Mild behavioral impairment (MBI) is an at-risk state for cognitive decline and dementia, characterized by emergent NPS in later life. MBI has significantly higher dementia incidence than late life psychiatric conditions. However, its utility as a proxy for neurodegeneration has not been demonstrated. Plasma neurofilament light (NfL) is a validated biomarker of axonal damage, and has been shown to associate with hallmarks of neurodegeneration. OBJECTIVE: The purpose of this investigation was to identify associations between NfL rate of change and the presence of MBI symptomatology. METHODS: We evaluated the association of MBI with changes in NfL in a cohort (n = 584; MBI + n = 190, MBI– n = 394) of non-demented participants from the Alzheimer’s Disease Neuroimaging Initiative. MBI was determined by transforming Neuropsychiatric Inventory Questionnaire items using a published algorithm. Change in NfL was calculated over 2 years. RESULTS: Time*MBI status was the only significant interaction to predict change in NfL concentrations (F(1,574) = 4.59, p = 0.032), even after controlling for age, mild cognitive impairment, and demographics. Analyses reclassifying 64 participants with new onset MBI over 2 years similarly demonstrated greater increases in NfL (F(1,574) = 5.82, p = 0.016). CONCLUSION: These findings suggest MBI is a clinical proxy of early phase neurodegeneration with putative utility in identifying those at dementia risk. MBI can be used as a case ascertainment approach to capture those at high risk for cognitive decline and dementia, and is an important construct for clinicians dealing with cognitive and neuropsychiatric symptomatology in older adults. IOS Press 2020-08-04 /pmc/articles/PMC7504997/ /pubmed/32597801 http://dx.doi.org/10.3233/JAD-200011 Text en © 2020 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Naude, James P. Gill, Sascha Hu, Sophie McGirr, Alexander Forkert, Nils D. Monchi, Oury Stys, Peter K. Smith, Eric E. Ismail, Zahinoor Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment |
title | Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment |
title_full | Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment |
title_fullStr | Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment |
title_full_unstemmed | Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment |
title_short | Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment |
title_sort | plasma neurofilament light: a marker of neurodegeneration in mild behavioral impairment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504997/ https://www.ncbi.nlm.nih.gov/pubmed/32597801 http://dx.doi.org/10.3233/JAD-200011 |
work_keys_str_mv | AT naudejamesp plasmaneurofilamentlightamarkerofneurodegenerationinmildbehavioralimpairment AT gillsascha plasmaneurofilamentlightamarkerofneurodegenerationinmildbehavioralimpairment AT husophie plasmaneurofilamentlightamarkerofneurodegenerationinmildbehavioralimpairment AT mcgirralexander plasmaneurofilamentlightamarkerofneurodegenerationinmildbehavioralimpairment AT forkertnilsd plasmaneurofilamentlightamarkerofneurodegenerationinmildbehavioralimpairment AT monchioury plasmaneurofilamentlightamarkerofneurodegenerationinmildbehavioralimpairment AT styspeterk plasmaneurofilamentlightamarkerofneurodegenerationinmildbehavioralimpairment AT smitherice plasmaneurofilamentlightamarkerofneurodegenerationinmildbehavioralimpairment AT ismailzahinoor plasmaneurofilamentlightamarkerofneurodegenerationinmildbehavioralimpairment AT plasmaneurofilamentlightamarkerofneurodegenerationinmildbehavioralimpairment |